Table 2 Clinical and pathological features associated with the metastatic tumors
|  | M0 at presentation (N = 90) | M1 (N = 68) | Total (N = 158) |
|---|---|---|---|
Year of Metastasectomy | |||
 Median | 1999 | 1998 | 1999 |
 Range | (1991–2005) | (1990–2004) | (1990–2000) |
Metastatic Site | |||
 BONE | 9 (10.0%) | 10 (14.7%) | 19 (12.0%) |
 BOWEL | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
 BRAIN | 7 (7.8%) | 4 (5.9%) | 11 (7.0%) |
 CONTRALATERAL ADRENAL | 3 (3.3%) | 5 (7.4%) | 8 (5.1%) |
 HEART | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
 IPSILATERAL ADRENAL | 2 (2.2%) | 8 (11.8%) | 10 (6.3%) |
 LIVER | 4 (4.4%) | 5 (7.4%) | 9 (5.7%) |
 MUSCLE | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
 NON-REGIONAL NODES | 9 (10.0%) | 1 (1.5%) | 10 (6.3%) |
 OMENTUM | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
 OTHER | 6 (6.7%) | 8 (11.8%) | 14 (8.9%) |
 PANCREAS | 5 (5.6%) | 2 (2.9%) | 7 (4.4%) |
 PULMONARY | 40 (44.4%) | 20 (29.4%) | 60 (38.0%) |
 SKIN | 2 (2.2%) | 2 (2.9%) | 4 (2.5%) |
 SPLEEN | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
 THYROID | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
Metastatic Grade | |||
 2 | 16 (17.8%) | 13 (19.1%) | 29 (18.4%) |
 3 | 60 (66.7%) | 36 (52.9%) | 96 (60.8%) |
 4 | 14 (15.6%) | 19 (27.9%) | 33 (20.9%) |
Metastatic Necrosis | |||
 No | 57 (63.3%) | 38 (55.9%) | 95 (60.1%) |
 Yes | 33 (36.7%) | 30 (44.1%) | 63 (39.9%) |
Metastatic Sarcomatoid | |||
 No | 86 (95.6%) | 62 (91.2%) | 148 (93.7%) |
 Yes | 4 (4.4%) | 6 (8.8%) | 10 (6.3%) |